Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination
verfasst von:
Pablo Pastor Pueyo, Elena Gambó Ruberte, Jara Gayán Ordás, Lucía Matute Blanco, Domingo Pascual Figal, José María Larrañaga Moreira, José Javier Gómez Barrado, David González Calle, Luis Almenar Bonet, Gonzalo Luis Alonso Salinas, Miguel José Corbí Pascual, María Plaza Martín, Jaume Pons Llinares, Alejandro Durante López, Manuel Barreiro Pérez, Fernando Candanedo Ocaña, Javier Bautista García, Germán Merchán Ortega, Fernando Domínguez Rodríguez, Virgilio Martínez Mateo, Marta Campreciós Crespo, Martín Quintás Guzmán, Laura Jordán Martínez, Jaime Aboal Viñas, Judit Rodríguez López, Sara Fernández Santos, Pablo Revilla Martí, Laura Álvarez Roy, Juan Carlos Gómez Polo, José Manuel García Pinilla, María Ferré Vallverdú, Lourdes García Bueno, Toni Soriano Colomé, Fernando Worner Diz
Vaccines against SARS-CoV-2 have been a major scientific and medical achievement in the control of the COVID-19 pandemic. However, very infrequent cases of inflammatory heart disease have been described as adverse events, leading to uncertainty in the scientific community and in the general population.
Methods
The Vaccine–Carditis Registry has included all cases of myocarditis and pericarditis diagnosed within 30 days after COVID-19 vaccination since August 1, 2021 in 29 centers throughout the Spanish territory. The definitions of myocarditis (probable or confirmed) and pericarditis followed the consensus of the Centers for Disease Control and the Clinical Practice Guidelines of the European Society of Cardiology. A comprehensive analysis of clinical characteristics and 3-month evolution is presented.
Results
From August 1, 2021, to March 10, 2022, 139 cases of myocarditis or pericarditis were recorded (81.3% male, median age 28 years). Most cases were detected in the 1st week after administration of an mRNA vaccine, the majority after the second dose. The most common presentation was mixed inflammatory disease (myocarditis and pericarditis). 11% had left ventricular systolic dysfunction, 4% had right ventricular systolic dysfunction, and 21% had pericardial effusion. In cardiac magnetic resonance studies, left ventricular inferolateral involvement was the most frequent pattern (58%). More than 90% of cases had a benign clinical course. After a 3-month follow-up, the incidence of adverse events was 12.78% (1.44% mortality).
Conclusions
In our setting, inflammatory heart disease after vaccination against SARS-CoV-2 predominantly affects young men in the 1st week after the second dose of RNA-m vaccine and presents a favorable clinical course in most cases.
Graphical abstract
×
Anzeige
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination
verfasst von
Pablo Pastor Pueyo Elena Gambó Ruberte Jara Gayán Ordás Lucía Matute Blanco Domingo Pascual Figal José María Larrañaga Moreira José Javier Gómez Barrado David González Calle Luis Almenar Bonet Gonzalo Luis Alonso Salinas Miguel José Corbí Pascual María Plaza Martín Jaume Pons Llinares Alejandro Durante López Manuel Barreiro Pérez Fernando Candanedo Ocaña Javier Bautista García Germán Merchán Ortega Fernando Domínguez Rodríguez Virgilio Martínez Mateo Marta Campreciós Crespo Martín Quintás Guzmán Laura Jordán Martínez Jaime Aboal Viñas Judit Rodríguez López Sara Fernández Santos Pablo Revilla Martí Laura Álvarez Roy Juan Carlos Gómez Polo José Manuel García Pinilla María Ferré Vallverdú Lourdes García Bueno Toni Soriano Colomé Fernando Worner Diz
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.
In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update Kardiologie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.